Germany indapamide market is estimated to grow significantly at a CAGR of around 3.6% during the forecast period. Due to the massive population of CVD, CHD, stroke, and rise in the adoption of indapamide drugs, the market is projected to grow considerably during the forecast period in Germany. The country has a quality healthcare system coupled with the cohesive government policies, that are driving the market in the region. As per the Institute for Health Metrics and Evaluation, around 192,000 cases of strokes were registered in the country in 2017 with a slight increment from 2014. Ischemic stroke is the leading stroke among all others in the country. As per Stroke Alliance for Europe (SAFE), in 2017 the prevalence of stroke was around 527,000 which is around 338 per 100,000 people. These high number of strokes prevalence in the country further increases the demand for indapamide in the country as it is used as the preventive treatment of stroke.
Germany indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.
The companies which are contributing to the growth of the Germany indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the Germany indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Germany Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. Germany Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Company Profiles
6.1. Bioindustria L.I.M. S.p.A.
6.2. Grupo Azevedos
6.3. Krka Group
6.4. Laboratori Baldacci S.p.A.
6.5. Merck KGaA
6.6. Mylan N.V.
6.7. Sandoz International GmbH
6.8. Sanofi S.A.
6.9. Servier Group
6.10. Teva Pharmaceuticals Industries Ltd.
1. GERMANY INDAPAMIDE MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2019-2026 ($ MILLION)
2. GERMANY INDAPAMIDE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2019-2026 ($ MILLION)
1. GERMANY INDAPAMIDE MARKET SHARE BY PRODUCT, 2019 VS 2026 (%)
2. GERMANY INDAPAMIDE MARKET SHARE BY APPLICATION, 2019 VS 2026 (%)